Caribou Biosciences (CRBU) Profit After Tax (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Profit After Tax data on file, last reported at -$25.1 million in Q1 2026.

• Profit After Tax for Q1 2026 came in at -$25.1 million, up 37.27% year-over-year; the trailing twelve-month figure through Mar 2026 was -$133.2 million (up 9.9% YoY), and the FY2025 annual result was -$148.1 million, up 0.67% from the prior year.
• Profit After Tax improved to -$25.1 million in Q1 2026 per CRBU's latest filing, from -$26.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$10.0 million in Q3 2023 and troughed at -$54.1 million in Q2 2025.
• A 5-year average of -$30.8 million and a median of -$28.0 million in 2023 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax soared 62.46% in 2023, then slumped 246.77% in 2024.
• A 5-year view of Profit After Tax shows it stood at -$27.0 million in 2022, then retreated by 27.85% to -$34.5 million in 2023, then slipped by 2.85% to -$35.5 million in 2024, then increased by 25.33% to -$26.5 million in 2025, then increased by 5.34% to -$25.1 million in 2026.
• Business Quant data shows CRBU's Profit After Tax at -$25.1 million in Q1 2026, -$26.5 million in Q4 2025, and -$27.5 million in Q3 2025.